No regression of renal amyloid mass despite remission of nephrotic syndrome in a patient with TRAPS following etanercept therapy

Journal of Nephrology

Volumn 23, Issue 1, 2010, Pages 119-123

  Simsek, Ismail ^a   Kaya, Ayper ^a   Erdem, Hakan ^a   Pay, Salih ^a   Yenicesu, Mujdat ^a   Dinc, Ayhan ^a  

^a GULHANE SCHOOL OF MEDICINE   (Turkey)

Author keywords

Amyloidosis; Anti TNF drugs; Autoinflammatory disease; Renal; TRAPS

Indexed keywords

COLCHICINE; ETANERCEPT;

ACUTE PHASE RESPONSE; ADULT; ARTICLE; CASE REPORT; FAMILIAL MEDITERRANEAN FEVER; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; KIDNEY AMYLOIDOSIS; KIDNEY BIOPSY; KIDNEY TUBULE BASEMENT MEMBRANE; MALE; NEPHROTIC SYNDROME; PROTEINURIA; RELAPSE; REMISSION; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED PERIODIC SYNDROME;

ADULT; AMYLOIDOSIS; BIOPSY; FAMILIAL MEDITERRANEAN FEVER; FOLLOW-UP STUDIES; HUMANS; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENTS; KIDNEY; MALE; NEPHROTIC SYNDROME; RECEPTORS, TUMOR NECROSIS FACTOR; SERUM AMYLOID P-COMPONENT; TREATMENT OUTCOME;

EID: 77249126433     PISSN: 11218428     EISSN: 17246059     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Hull KM, Drewe E, Aksentijevich I, et al. The TNF receptor-associated periodic syndrome (TRAPS): emerging concepts of an autoinflammatory disorder. Medicine. 2002;81:349-368.
2. McDermott MF, Aksentijevich I, Galon J, et al. Germline mutations in the extracellular domains of the 55 kDa TNF receptor, TNFR1, define a family of dominantly inherited autoinflammatory syndromes. Cell. 1999;97:133-144.
3. Drewe E, Huggins ML, Morgan AG, Cassidy MJ, Powell RJ. Treatment of renal amyloidosis with etanercept in tumour necrosis factor receptor-associated periodic syndrome. Rheumatology (Oxford). 2004;43:1405-1408.
4. Jadoul M, Dode C, Cosyns JP, et al. Autosomal-dominant periodic fever with AA amyloidosis: novel mutation in tumor necrosis factor receptor 1 gene [rapid communication]. Kidney Int. 2001;59:1677-1682.
5. Kallinich T, Briese S, Roesler J, et al. Two familial cases with tumor necrosis factor receptor-associated periodic syndrome caused by a non-cysteine mutation (T50M) in the TNFRSF1A gene associated with severe multiorganic amyloidosis. J Rheumatol. 2004;31:2519-2522.
6. Simon A, Dode C, van der Meer JW, Drenth JP. Familial periodic fever and amyloidosis due to a new mutation in the TNFRSF1A gene. Am J Med. 2001;110:313-316.
7. Elkayam O, Hawkins PN, Lachmann H, Yaron M, Caspi D. Rapid and complete resolution of proteinuria due to renal amyloidosis in a patient with rheumatoid arthritis treated with infliximab. Arthritis Rheum. 2002;46:2571-2573.
8. Fernandez-Nebro A, Tomero E, Ortiz-Santamaria V, et al. Treatment of rheumatic inflammatory disease in 25 patients with secondary amyloidosis using tumor necrosis factor alpha antagonists. Am J Med. 2005;118:552-556.
9. Gottenberg JE, Merle-Vincent F, Bentaberry F, et al. Antitumor necrosis factor alpha therapy in fifteen patients with AA amyloidosis secondary to inflammatory arthritides: a followup report of tolerability and efficacy. Arthritis Rheum. 2003;48:2019-2024.
10. Smith GR, Tymms KE, Falk M. Etanercept treatment of renal amyloidosis complicating rheumatoid arthritis. Intern Med J. 2004;34:570-572.
11. Gillmore JD, Lovat LB, Persey MR, Pepys MB, Hawkins PN. Amyloid load and clinical outcome in AA amyloidosis in relation to circulating concentration of serum amyloid A protein. Lancet. 2001;358:24-29.
12. Dinc A, Erdem H, Rowczenio D, et al. Autosomal dominant periodic fever with AA amyloidosis: tumor necrosis factor receptor-associated periodic syndrome (TRAPS) in a Turkish family. J Nephrol. 2005;18:626-629.
13. Drewe E, McDermott EM, Powell PT, Isaacs JD, Powell RJ. Prospective study of anti-tumour necrosis factor receptor superfamily 1B fusion protein, and case study of anti-tumour necrosis factor receptor superfamily 1A fusion protein, in tumour necrosis factor receptor associated periodic syndrome (TRAPS): clinical and laboratory findings in a series of seven patients. Rheumatology (Oxford). 2003;42:235-239.
14. Drewe E, McDermott EM, Powell RJ. Treatment of the nephrotic syndrome with etanercept in patients with the tumor necrosis factor receptor-associated periodic syndrome. N Engl J Med. 2000;343:1044-1045.
15. Metyas S, Arkfeld DG, Forrester DM, Ehresmann GR. Infliximab treatment of familial Mediterranean fever and its effect on secondary AA amyloidosis. J Clin Rheumatol. 2004;10:134-137.
16. Ravindran J, Shenker N, Bhalla AK, Lachmann H, Hawkins P. Case report: response in proteinuria due to AA amyloidosis but not Felty's syndrome in a patient with rheumatoid arthritis treated with TNF-alpha blockade. Rheumatology (Oxford). 2004;43:669-672.
17. Verschueren P, Lensen F, Lerut E, et al. Benefit of anti-TNFalpha treatment for nephrotic syndrome in a patient with juvenile inflammatory bowel disease associated spondyloarthropathy complicated with amyloidosis and glomerulonephritis. Ann Rheum Dis. 2003;62:368-369.
18. Looi LM. Histomorphological variations in systemic AA amyloidosis: clues of AA protein polymorphism. Histopathology. 1989;14:111-120.
19. Oner A, Erdogan O, Demircin G, Bulbul M, Memis L. Efficacy of colchicine therapy in amyloid nephropathy of familial Mediterranean fever. Pediatr Nephrol. 2003;18:521-526.
20. Lachmann HJ, Goodman HJ, Gilbertson JA, et al. Natural history and outcome in systemic AA amyloidosis. N Engl J Med. 2007;356:2361-2371.
21. Yan SD, Zhu H, Zhu A, et al. Receptor-dependent cell stress and amyloid accumulation in systemic amyloidosis. Nat Med. 2000;6:643-651.
22. Tanaka N, Yonekura H, Yamagishi S, Fujimori H, Yamamoto Y, Yamamoto H. The receptor for advanced glycation end products is induced by the glycation products themselves and tumor necrosis factor-alpha through nuclear factor-kappa B, and by 17beta-estradiol through Sp-1 in human vascular endothelial cells. J Biol Chem. 2000;275:25781-25790.
23. Pai R, Ha H, Kirschenbaum MA, Kamanna VS. Role of tumor necrosis factor-alpha on mesangial cell MCP-1 expression and monocyte migration: mechanisms mediated by signal transduction. J Am Soc Nephrol. 1996;7:914-923.
24. McCarthy ET, Sharma R, Sharma M, et al. TNF-alpha increases albumin permeability of isolated rat glomeruli through the generation of superoxide. J Am Soc Nephrol. 1998;9:433-438.
25. Raveh D, Shemesh O, Ashkenazi YJ, Winkler R, Barak V. Tumor necrosis factor-alpha blocking agent as a treatment for nephrotic syndrome. Pediatr Nephrol. 2004;19:1281-1284.
26. Tomlinson L, Davies K, Wright DA, Holt S. Granulomatous interstitial nephritis treated with a tumour necrosis factor-alpha inhibitor. Nephrol Dial Transplant. 2006;21:2311-2314.